Inrebic (Fedratinib)

Fedratinib selectively blocks the activity of Janus kinase 2 (JAK2), a key enzyme in the JAK‑STAT signaling pathway. Inhibiting JAK2 reduces abnormal cell proliferation and cytokine production that drive the pathology of myelofibrosis.

The dosage of Inrebic is individualized by the prescribing clinician based on the patient’s clinical status, laboratory values, and treatment response. Only a qualified healthcare professional should determine the appropriate dosing regimen.

The safety of Fedratinib in pregnancy and lactation has not been established. It should be used only if the potential benefit justifies the potential risk to the fetus or infant, and women should discuss contraception and breastfeeding plans with their physician.

To place an order, submit an enquiry on the Inrebic product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details, and any necessary import documentation.

Inrebic (Fedratinib) is a selective JAK2 inhibitor, whereas other agents such as ruxolitinib target both JAK1 and JAK2. Fedratinib may be preferred in patients who have progressed on or are intolerant to broader JAK inhibitors, but therapeutic choice depends on individual patient factors and physician judgment.

Inrebic tablets should be stored at ambient temperature, below 25 °C, in the original container to protect them from moisture and light. Do not store in areas with high humidity or extreme heat.

Inrebic is taken orally as a tablet, usually with water. The exact timing and whether it should be taken with food are determined by the prescribing clinician based on the patient’s overall treatment plan.

Serious risks include Wernicke encephalopathy, severe infections, hepatic toxicity, tumor lysis syndrome, cardiac failure, and pulmonary hypertension. Patients should be monitored closely for neurological symptoms, liver function changes, and signs of infection throughout therapy.

Inrebic is contraindicated in patients with known hypersensitivity to Fedratinib or any tablet excipients. Caution is advised for individuals with pre‑existing severe liver disease, active infections, or a history of Wernicke encephalopathy. The drug should not be used without medical supervision.